Recent Finacing
Recent Raise
Theravectys develops lentiviral vector vaccines engineered to transduce dendritic cells in vivo and elicit T‑cell immunity, advancing infectious-disease and cancer candidates with in‑house GMP manufacturing.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Theravectys.
